A lone figure, silhouetted, sitting with a wide sky and horizon ahead
Frank McKenna (frankiefoto)
Illustrative. Not a participant in any of the reviewed studies or a photograph of anyone taking a GLP1 drug.
The GLP1 Suicide Scare Didn't Survive 4.9 Million Patients
I have been sitting on the GLP1 and mental health question for three years now, because every piece of coverage I found was either a scare built on a handful of case reports or a reassurance built on nothing more solid than a press release. That changed on September 6, when a systematic review pooling more than 4.9 million patients finally gave the question a real answer, and it is more interesting than either extreme.
- A new systematic review pooling 11 studies and more than 4.9 million patients on GLP1 drugs found no classwide increase in psychiatric risk, and several studies found a protective link instead.
- One large multinational registry tied GLP1 use to a 17 percent lower risk of suicide death or self harm, and semaglutide specifically was linked to a 28 percent lower risk of psychiatric hospitalization in people who already had depression or anxiety.
- There is one real exception. An obesity focused cohort found nearly three times the risk of major depression and roughly double the risk of anxiety and suicidal thoughts, and researchers could not fully explain it away.
- Every study here is observational, so this settles the classwide alarm far more than it proves cause and effect in either direction.
What a review of 4.9 million patients actually found
The review, published in the journal Cureus, followed the PRISMA method for systematic reviews. The authors searched from 2021 through May 2026 across PubMed, Google Scholar and ScienceDirect, narrowing 617 records down to 11 primary studies, mostly large cohort studies, after quality appraisal. The populations came from the United States, the United Kingdom, Scandinavia and Poland, and everyone included was being treated with a GLP1 drug for type 2 diabetes or obesity.
Nine of those ten cohort studies found either no increase in psychiatric risk or an outright protective link. One large multinational registry tied GLP1 use to roughly a 17 percent lower risk of suicide death combined with non fatal self harm, compared with people not on the drug. A second registry found roughly a 10 percent lower risk of suicidal ideation, attempt or intentional self harm. One study compared GLP1 users directly against people on other diabetes drugs and found no increased risk against SGLT2 inhibitors, and a lower risk than DPP4 inhibitors. Semaglutide specifically was linked to a 28 percent lower risk of psychiatric hospitalization or self harm among patients who already had depression or anxiety before starting the drug. The United States Food and Drug Administration's own post marketing safety review reached a similar conclusion through a completely different route, finding that the available evidence did not support a causal link between GLP1 drugs and suicidal behavior.
The one cohort that didn't fit
The exception is worth taking seriously rather than waving away, because it happens to be the population most Sama Says readers actually belong to. One cohort in the review, led by researcher Kornelius and focused specifically on patients treated for obesity rather than diabetes, found nearly three times the risk of a major depressive disorder diagnosis, and roughly double the risk of anxiety and suicidal ideation or attempts. The review's own authors floated one likely explanation, surveillance bias: weight management clinics tend to screen for mood symptoms more aggressively than a general diabetes clinic does, so they are simply diagnosing more of what was already there. But they were explicit in the paper that this may not account for the entire gap, and I think that honesty is exactly why the finding deserves airtime rather than a footnote.
Studies found no rise in risk, or a protective link
Including a 17% lower risk of suicide death or self harm in one registry, and a 28% lower risk of psychiatric hospitalization with semaglutide.
Cohort dissented sharply
An obesity focused population showed nearly three times the risk of major depression, and roughly double the risk of anxiety and suicidal thoughts.
All 11 studies in the review were observational. None can prove cause and effect in either direction.
Don't let this drift into GLP1s treat depression
The same review includes a smaller, separate finding about whether GLP1 drugs might actually improve mood, and it is far weaker evidence than the safety finding above. Only one study in the entire review, led by researcher Witaszek and covering 1,105 adult women, used validated psychometric mood scales rather than diagnostic codes. It found that semaglutide users had modestly but significantly lower depression and anxiety scores than non users. That is a real, interesting signal from a single study, not a demonstrated antidepressant effect, and it is the kind of claim that tends to get rounded up in headlines far more confidently than the underlying data supports.
Honest caveat
All 11 studies in this review are observational, and not one of them was a randomized controlled trial with psychiatric safety or antidepressant benefit as its primary goal, so nothing here proves cause and effect in either direction. The review itself was not registered in advance, did not apply a formal certainty framework like GRADE, and synthesized its findings narratively rather than by statistically pooling them. Cureus is a rapid review journal with a lower publication bar than many established medical journals. Most of the underlying studies relied on diagnostic codes rather than mood scales, which capture that someone received a diagnosis, not how they actually felt. And the antidepressant potential finding rests on that single cross sectional study of 1,105 women, which is the weakest link that caps how confident any of this can be.
What this means for you
If you are on a GLP1 drug for diabetes or obesity and have been carrying three years of scary headlines with nothing solid to weigh them against, this review is the most solid reassurance available so far. But it does not erase every open question. If your reason for taking one of these drugs is obesity specifically, rather than diabetes, the one cohort that dissented sharply is the population you actually belong to, so it is worth paying honest attention to your own mood and mentioning any real changes to your prescriber rather than assuming the reassuring population level data automatically applies to you. And resist the pull toward the opposite overclaim too: this review is not evidence that GLP1 drugs treat depression.
Primary sources
- Quadir A, Devi R, Jad Allah B, Haider A, Shaikh SS, Botsa KN. "Impact of Glucagon-Like Peptide-1 Receptor Agonists on Mental Health: A Systematic Review of Psychiatric Safety and Antidepressant Potential." Cureus, 2026.
- News Medical, "GLP1 drugs appear psychiatrically safe but one finding still raises questions," September 6, 2026.
Common questions
Does this mean GLP1 drugs are proven safe for mental health?
Not proven in the strict sense. Every one of the 11 studies in this review was observational, meaning none can establish cause and effect in either direction. What it does show is that the sharpest fears about a classwide psychiatric risk have not held up against 4.9 million patients, with most studies finding no increased risk or a protective link instead.
What about people taking GLP1 drugs for obesity specifically, not diabetes?
This is the one place the reassurance gets more complicated. The single cohort that dissented sharply, finding close to three times the risk of major depression and roughly double the risk of anxiety and suicidal thoughts, was an obesity focused population. Researchers suspect part of that gap comes from weight management clinics screening and diagnosing more aggressively, but they were explicit that this may not explain all of it.
Do GLP1 drugs actually treat depression?
That is a much weaker claim than the safety finding, and this review does not support it. Only one study in the whole review used validated mood scales rather than diagnostic codes, and it found a modest difference in a specific population of 1,105 women. That is not enough evidence to call these drugs an antidepressant.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.